Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, 1090 Vienna, Austria.
Takeda Pharmaceuticals International AG, 8152 Glattpark, Switzerland.
Nutrients. 2024 Nov 1;16(21):3762. doi: 10.3390/nu16213762.
This study aimed to gain real-world insights from healthcare professionals (HCPs) regarding the management of adult patients with short bowel syndrome and intestinal failure (SBS-IF) who received teduglutide and achieved parenteral support (PS) independence or PS volume stability for ≥12 months.
This cross-sectional survey was conducted in five European countries and Canada via a self-reported questionnaire (November 2022-March 2023) among HCPs who manage patients with SBS-IF and who had prescribed teduglutide to ≥5 patients with SBS-IF receiving PS.
Of the 70 HCPs who completed the survey, almost all reported managing patients with SBS-IF who achieved PS independence or PS volume stability (99%, 69/70 and 97%, 68/70, respectively) and maintained the standard teduglutide dose, without changes. A total of 52 HCPs managed patients who achieved PS independence and discontinued teduglutide. Of these HCPs, 73% (38/52) anticipated that these patients would remain PS-independent, not requiring PS reintroduction. Of the remainder, 79% (11/14) estimated that ≤40% of these patients would require PS reintroduction. While many HCPs (81%, 42/52) would reintroduce teduglutide in patients who discontinued its use after achieving PS independence, none would do so for patients who discontinued teduglutide after achieving PS volume stability if a patient's condition worsened.
This survey found that patients with SBS-IF can achieve PS independence or PS volume stability with teduglutide treatment. However, some HCPs (27%, 14/52) believe that a proportion of patients discontinuing teduglutide after achieving PS independence will require PS reintroduction. This survey suggests that teduglutide treatment should continue uninterrupted, unless clinically indicated, but this requires confirmation in future studies.
本研究旨在从医疗保健专业人员（HCP）那里获得真实世界的见解，了解接受特杜鲁肽治疗并实现肠外支持（PS）独立或 PS 容量稳定≥12 个月的成年短肠综合征和肠衰竭（SBS-IF）患者的管理情况。
这项横断面调查于 2022 年 11 月至 2023 年 3 月在五个欧洲国家和加拿大进行，通过自我报告问卷（70 名管理 SBS-IF 患者且至少为 5 名接受 PS 的 SBS-IF 特杜鲁肽患者开具处方的 HCP）调查了 HCP。
在完成调查的 70 名 HCP 中，几乎所有的 HCP 都报告管理着实现 PS 独立或 PS 容量稳定的 SBS-IF 患者（99%，69/70 和 97%，68/70），并保持特杜鲁肽标准剂量不变。共有 52 名 HCP 管理着实现 PS 独立并停止使用特杜鲁肽的患者。在这些 HCP 中，73%（38/52）预计这些患者将保持 PS 独立，无需再次引入 PS。其余的，79%（11/14）估计这些患者中≤40%需要再次引入 PS。虽然许多 HCP（81%，42/52）会在实现 PS 独立后停止使用特杜鲁肽的患者中重新引入特杜鲁肽，但如果患者病情恶化，他们不会在实现 PS 容量稳定后停止使用特杜鲁肽的患者中重新引入特杜鲁肽。
这项调查发现，SBS-IF 患者可以用特杜鲁肽治疗实现 PS 独立或 PS 容量稳定。然而，一些 HCP（27%，14/52）认为，一部分在实现 PS 独立后停止使用特杜鲁肽的患者将需要重新引入 PS。这项调查表明，除非临床需要，否则特杜鲁肽治疗应不间断继续，但这需要在未来的研究中得到证实。
